clinical trial · NCT06796998
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Izidore Lossos, MD·phase2·recruiting·n = 25
Marginal Zone LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueSplenic Marginal Zone LymphomaNodal Marginal Zone LymphomaEpcoritamab
brief summary
The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
started
Oct 13, 2025
primary completion
Oct 15, 2028
completion
Apr 15, 2031
last updated
Oct 28, 2025
official title
Phase 2 Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol